Clinical TrialsWith MIRACLE now enrolling and dosing patients in the US, clearance for EU sites to start up and positioned for unblinded interim data, Moleculin should be positioned to unlock value on the data readout.
Financial PerformanceThe company was able to successfully complete two transactions under more favorable terms, including a warrant inducement transaction and a registered direct offering, which combined raised $9.3M.
Regulatory ApprovalsAnnamycin currently has Fast Track and Orphan Drug Designation from the FDA for the treatment of R/R AML, increasing potential to accelerate its timeline for approval.